Previous Meetings
|
|
|
|
|
| October 6th, 2011 | ADME in NAFLD: Increased Risk of Adverse Drug Reactions | Nathan Cherrington, Ph.D | |
| May 26th, 2011 | The Basis for the Clinical Interaction Between Clopidogrel and Proton Pump Inhibitors (PPIs) | Andrew Parkinson, Ph.D | Click Here |
| March 17th 2011 | Symposium : Drug Transporters: What's All the Flux about? | Joseph W. Polli, Ph.D Thomas J. Raub, Ph.D Raymond Evers, Ph.D Aleksandra Galetin, Ph.D Alex Sparreboon, Ph.D | |
Summer 2010
|
Ethnicity and Global Drug Development: Focus on Asia |
Bob Powell, Ph.D |
|
March 4th, 2010 |
SYMPOSIUM: Drug-Drug Interactions |
Haig Bozigian, Ph.D Steve Castellino, Ph.D Chris Kemper, Ph.D Michael Devito, Ph.D Paul Watkins, MD |
Click Here Click here Click here |
| December 10, 2009 | Role of Transporter in the Blood-Brain Barrier in the CNS Distribution of Drugs: In Vitro – In Vivo Correlation | Professor of Department of Pharmaceutics, School of Pharmacy, University of Minnesota, Minneapolis, MN | Click here |
December 10, 2009 |
Medicinal Chemical Strategies to Reduce Transporter-Mediated Efflux for Delivery of Xenobiotics Across the Blood-Brain Barrier |
Robert T. Jacobs, Ph.D: Director of Chemistry, SCYNEXIS, Inc. |
|
September 17, 2009 |
Blood, Bone, and Biology: Pharmacokinetics and the Discovery of Human Biotherapeutics |
Paul G. Pearson, Ph.D., President and CEO, Pearson Pharma Partners |
|
| March 5, 2008 | Quantitative Proteomics and Its Application to ADME | Senior Director, Medical Sciences Amgen, Inc. Clinical Applications of Quantitative Proteomics | |
| December 6, 2007 | Pharmacogenomics: Science and Translation | Dr. Richard M. Weinshilboum Mayo Clinic College of Medicine | |
|
October 17, 2007 | "Challenges Posed by a New Draft FDA Guidance on the Safety Assessment of Drug Metabolites" | Dr. Clay B. Frederick Merck & Co., Inc. | Click here |
March 1, 2007 | SYMPOSIUM: Drug-Drug Interactions | Dr. Brian Houston University of Manchester Dr. Punit Marathe Bristol-Myers-Squibb Dr. Marrilyn Morris The State University of New York Dr. Soraya Madani Novartis Pharmaceutical Corporation Dr. John Murphy University of Arizona | |
| November
14, 2006 | "Current
Issues with Drug Metabolism in Drug Development" | Dr. Gerald Miwa Millennium Pharmaceuticals | |
| May 18,
2006 | "Is There
an Impact of CYP3A5 Expression on CYP3A-mediated Drug Interactions?" | Dr. Steve Hall Indiana University | |
| September 22, 2004 | Noninvasive Assessment of CYP3A
Activity "The Eye as a Window on Drug Metabolism" | Dr. Evan D. Kharasch University of Washington |
|
| May 19, 2004 |
Smoking, Cancer, and CYP2A6" |
University of Toronto |
|
| February 24, 2004 | SYMPOSIUM: Drug Transporters |
GlaxoSmithKline Dr. Leslie Z. Benet Dr. Kim L. R. Brouwer Dr. David S. Miller Dr. Gordon L. Amidon | |
|
|
|
University of Kansas at Lawrence |
|
|
|
P-glycoprotein - are they clinically important?" |
Vanderbilt University |
|
|
March 5, 2003
|
|
RTI International Dr. Thomas Walle Dr. John Cardellina Joe Graedon, M.S. and Dr. Teresa Graedon | |
|
|
|
The Scripps Research Institute |
|
|
|
|
Brookhaven National Laboratory Dr. Timothy DeGrado Dr. Jerry Collins |
|
|
|
|
Fox Chase Cancer Center |
|
|
|
A Pragmatic View of the Issue of Reactive Intermediates" |
Department of Drug Metabolism, Merck Research Laboratories |
|
| May 15, 2001 | "Genetic approaches to study metabolism and transport" | Dr. Erin Schuetz St. Jude Children’s Research Hospital | Click Here |
|
|
|
Eli Lilly |
|
|
|
Example with Retinoic Acid and Cross-Species Extrapolation of Metabolism and Teratogenicity" |
ICF Consulting |
|
|
|
Do We Keep Score of ADR's or Do Something About It?" |
Glaxo Wellcome |
|
|
|
|
Vanderbilt University |
|
|
Inaugural Meeting |
"Citrus Juices and Intestinal Barrier Function in Man: Not Pulp Fiction" |
University of North Carolina at Chapel Hill |
|